Question 1

What is DSIP?

Accepted Answer

DSIP stands for delta sleep-inducing peptide, and the name describes what it did to rabbits in the 1970s. A Swiss group kept donor rabbits asleep by electrical stimulation of a deep brain region, then infused fluid from their circulation into other rabbits, which slept. From 1970 to 1977 that team isolated, characterized and synthesized a nonapeptide called delta-sleep-inducing peptide responsible for this effect. A nonapeptide is a chain of nine amino acids. The body appears to carry it already. Both DSIP and a modified form of it occur in human CSF, the fluid around the brain and spine, and DSIP-like material has been found in human urine and milk as well. What is sold under this name is a synthetic copy of something people already produce, rather than a molecule foreign to the body.

Question 2

Does DSIP actually make you sleep?

Accepted Answer

In animals something measurable happens, and which thing depends on the animal. A 1984 review reports that DSIP induced mainly delta-sleep in rabbits, rats, mice, and humans, whereas in cats, the effect on REM sleep was more pronounced. Delta sleep is the deepest stage of non-dreaming sleep, identified by slow electrical waves across the cortex. A second 1984 review states that giving DSIP into a vein produced, in different animals, sleep lasting for hours. At 25 micrograms per kilogram into a vein, DSIP augmented spindle-dominated, light nonREM sleep and prevented hyposomnia after a stressful situation, meaning the animals did not lose sleep after stress. In rabbits the extra sleep was light sleep, in cats it was dreaming sleep, and the species that matters to a reader has the thinnest file.

Question 3

What did the human sleep studies measure?

Accepted Answer

Three recorded sleep in people given DSIP, all of them in the 1980s. The first tested acute intravenous administration of synthetic DSIP, 25 nmoles/kg b.wt, on disturbed human sleep in 6 middle-aged chronic insomniacs. It reported longer sleep duration and a higher quality of sleep with fewer interruptions, and no day-time sedation. The timing was odd: sleep-promoting effects occurred only in the second hour after injection, in the first hour a slight arousing effect was indicated. A 1984 paper collected several investigations. Nmol/kg means the amount was scaled to each person's body weight. Two different studies showed improvement of sleep following single injections of 25 nmol/kg b.w. before sleep, and repeated administrations indicated a buildup with normalization of sleep structure after four administrations. Then a 1987 investigation measured it against placebo. DSIP in a dose of 25 nmol/kg or a placebo was administered i.v. during four nights using a double-blind crossover design. Waking time fell, but no significant differences were found in comparison to baseline or to double-blind placebo nights. The authors concluded that sleep improvement under DSIP treatment is of little clinical significance.

Question 4

Why is the sleep evidence still unsettled?

Accepted Answer

Because the controlled study is the one that came back empty, and because the answer moves with the clock. A 2003 review of how non-dreaming sleep is regulated lists DSIP as one of four sleep factors found by transfer experiments, in which fluid from sleeping animals was injected into others. That review then says a physiological sleep regulatory role, however, has not been determined for these substances. When DSIP was infused into the brain ventricles of freely moving rats for 10 hours during the day, the infusion brought about almost no change in sleep parameters, in contrast to a nocturnal infusion which may result in marked sleep-promoting effects. A 1997 review of neuropeptides and human sleep reached the same place, stating that the impact of delta sleep-inducing peptide on human sleep regulation is not yet clear. Weigh the two human designs against each other. The unblinded study found an effect and the blinded one did not, the ordinary pattern when an effect is small or carried by expectation.

Question 5

What else has DSIP been studied for?

Accepted Answer

Seizures, stroke and stress, all of it in rodents, and none of those experiments recorded sleep. In rats given a chemical that triggers sound-induced seizures, DSIP and a close analogue decreased the incidence, mean seizure grade and duration of the convulsions. A later experiment in the same rat model paired DSIP with an ineffective quantity of valproate, an anti-seizure medicine. Neither alone changed anything, but their combination significantly prolonged latency to seizure during 6 h after injection. A 2021 study gave DSIP to Sprague-Dawley rats through the nose before and after an artery in the brain was blocked. Brain infarction in DSIP-treated animals was smaller than in vehicle-treated animals, the difference was not significant, however motor performance in the rotarod test significantly recovered. Stress work in rats found that DSIP administration induced marked changes in substance P, beta-endorphin and stress hormone levels in the hypothalamus and blood plasma. That is a wide spread of findings in rodents. None of it is about sleep. A sleep claim needs a sleep measurement, and none of these experiments took one.

Question 6

Is DSIP something the body already makes?

Accepted Answer

Yes, and people have been measured. DSIP-like material was found by RIA and immunohistochemistry in brain and by RIA in peripheral organs of the rat as well as in plasma of several mammals, using two laboratory methods for finding a molecule in tissue. Two studies tracked a person's own levels. Among 44 people assessed in hospital after a suicide attempt, patients with major depressive disorders had significantly lower DSIP in spinal fluid than other patients. In five healthy men measured every half hour across two 24-hour periods, one of ordinary activity and one of constant bed rest during 34 h, the concentrations of DSIP and its modified form showed no or minimal changes between the two conditions. Read those carefully. They measure the DSIP a person already carries, rather than the consequences of administering more. A concentration that moves with depression establishes the peptide as part of human physiology, and says nothing about what an injection does.

Question 7

Does DSIP do anything to hormones?

Accepted Answer

Two human studies looked, and both came back negative. The first administered DSIP intravenously to eight healthy women and tracked growth hormone and prolactin, the hormone behind milk production. Serum GH and PRL levels were normal under basal conditions and no effects were noted after the infusion of DSIP, and the daily rhythm of both was unchanged. The authors add that this was at dosages which are known to modify ECG patterns, so the amount was not trivially small. The second tested the stress axis in healthy young men. Responses of ACTH and cortisol, the pituitary signal and the stress hormone it drives, were almost identical during and after infusion of DSIP and placebo, and the usual midday surge of both after a meal was also not affected. The authors wrote that their data do not support an inhibitory role of DSIP on ACTH and cortisol secretion in man. Four hormones in healthy volunteers, all unchanged, is a narrow slice of the endocrine question, and the clearest human measurement available.

Question 8

How does DSIP make you feel?

Accepted Answer

No study among the research behind this page asked anyone that question directly. What exists is a set of observations recorded around sleep, pointing in two directions at once. In the six insomniacs given a single dose, the authors reported no day-time sedation or other side effects, and the sleep-promoting effect arrived only in the second hour, with a slight arousing effect indicated in the first hour. The 1984 summary of repeated dosing is stranger still: repeated injections in the morning, besides increasing daytime activity, still had a strong positive effect on night sleep, but not so two doses daily. Animal work points at wakefulness as well as sleep. A 1984 review reports that DSIP acts upon the circadian rhythmicity of the locomotor activity and transmitter concentrations in the brain, meaning the daily pattern of movement shifted. Those are recordings of activity and sleep stages, rather than accounts of how anyone felt. The distinction matters for a compound purchased on a reported sensation.

Question 9

How long does DSIP last?

Accepted Answer

Two numbers answer that, and they are easy to confuse. The first is how fast the molecule breaks down. A 1984 review reports the half-life time for proteolytic split-off of tryptophan by brain slices and homogenates is 15 min, which is a measurement in brain tissue preparations rather than in a living person. The same review notes that the body's own supply behaves differently inside a living human or animal: endogenous DSIP-like material in plasma, urine and CSF was found to be bound to a larger protein and thus protected from breakdown. The second number is how long an effect lasted. In the 1981 insomnia study the sleep enhancing capacity was seen for up to 6 h of night sleep after one injection. In the rat seizure work, valproate reached a peak of action immediately after the application, while DSIP had a prolonged action, with its dose-response measured four hours after injection. Minutes in a tissue preparation and hours in a sleeping person are not the same measurement, and only the second was measured in people.

Question 10

When is the best time of day to take DSIP?

Accepted Answer

The studies answer a narrower question than the one being asked. In rats, DSIP infused into the brain ventricles for 10 hours in the daytime produced almost no change in sleep parameters, against marked sleep-promoting effects from the same infusion at night. The authors proposed that an endogenous sleep substance should be characterized by a property not to cause excessive sleep at the time when sleep is physiologically saturated. In plain terms, a rat already sleeping its fill does not sleep more. In the human work, injections were given before sleep. The same 1984 summary records morning injections, which increased daytime activity in patients and still had a strong positive effect on night sleep, while two doses daily did not. A 1984 review reports a U-shaped activity curve for the dose as well as for the time of infusion. Neither a larger quantity nor an earlier injection moves the result in a straight line, so no timing rule can be read off this literature.

Question 11

Where do I inject DSIP?

Accepted Answer

Published work used several routes, and each was chosen to suit an experiment rather than a person. Every human sleep study above gave DSIP into a vein. The animal literature is wider. A 1984 review reports that infusion into the brain ventricles, injection into a vein and injection under the skin yielded a parabolic dose-response curve with different effective optima, meaning the amount that worked best differed by route. Rabbit experiments used both a vein and the skin, at quantities forty-fold apart. The 2021 stroke study applied DSIP nasally to rats. The same 1984 review notes that unweaned rats are able to take up DSIP by the intestinal tract. Route matters because of where the molecule has to reach: a 1983 review places DSIP among peptides that enter the cerebrospinal fluid to a slight or moderate extent in the intact form. None of that establishes a route for a person. Route and quantity were paired inside each experiment, so a route lifted out of one arrives without the quantity that made it work. It is the DSIP dosage page that holds the quantities, each one tied to the species and the experiment it came from.

Question 12

What is documented about DSIP side effects?

Accepted Answer

Very little, and what there is comes from six people in 1981. That study reported no day-time sedation or other side effects after a single injection into a vein. Six middle-aged insomniacs, one night each, in 1981, is the whole adverse-event record among the research behind this page. A 2026 review that covers DSIP among recovery-enhancing peptides states that although preclinical studies are promising, there is a current lack of clinical trials. Animal work speaks to a different question. Sixteen DSIP analogues were tested against poisoning by cisplatin, a chemotherapy medicine, and one of them cut animal deaths from acute cisplatin toxicity to 17%, against 50-67% for the control animals. That is protection against a specific poison in rodents, rather than a safety record for DSIP in people. Reported adverse effects, interactions and who was left out of these studies are set out on the DSIP safety page.

Question 13

Is DSIP approved anywhere?

Accepted Answer

No approval for DSIP in any country is documented among the research behind this page. The closest thing to a regulatory statement comes from a 2026 review of peptides in bone and joint care. It groups delta sleep-inducing peptide with epithalon and pinealon as recovery agents, and it reports a current lack of clinical trials. A compound whose human file stops in 1987 gives a regulator very little to read. Two points matter for anyone reading vendor copy. The human work used material made for research and given into a vein under medical watch, which is not what is sold now. The name is also slippery. A 2009 review reports that a thing called the delta sleep-inducing peptide immunoreactor is in fact a different protein, so papers carrying the DSIP name are not always about this peptide.

Question 14

How is DSIP thought to work?

Accepted Answer

This is the thinnest part of the file. A 2003 review that lists DSIP among the classical sleep factors says that a physiological sleep regulatory role, however, has not been determined for these substances. No receptor for it is named in the research behind this page. The older work did show that the exact molecule matters. In those animal experiments, analogs with exchanged amino acids in the sequence or shortening the peptide by one or two amino acids decreased or abolished the effect. So did breakdown products, suggesting a close structure-specificity. Something recognises the intact nine-amino-acid chain. Nothing in this literature names what. Around that sit scattered findings from animal work: shifts in brain transmitter levels, shifts in the daily rhythm of movement, and a brain concentration of DSIP that increased during progressed hibernation in animal species. A 2026 review describes DSIP as targeting circadian and mitochondrial regulators, which names a category rather than a demonstrated pathway.

DSIP